Nature Search

Angiotensin II Type 1 Receptor Blocker Prevents Atrial Structural Remodeling in Rats with Hypertension Induced by Chronic Nitric Oxide Inhibition

Hidetoshi Okazaki
Tetsuo Minamino
Masafumi Kitakaze
Research01 Apr 2006
Hypertension Research

Volume: 29, P: 277-284
Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart Failure: A Prospective Open-Randomized Study

Shoji Sanada
Hiroshi Asanuma
Masatsugu Hori
Research01 Oct 2007
Hypertension Research

Volume: 30, P: 913-919
Atorvastatin Slows the Progression of Cardiac Remodeling in Mice with Pressure Overload and Inhibits Epidermal Growth Factor Receptor Activation

Yulin Liao
Hui Zhao
Masafumi Kitakaze
Research01 Feb 2008
Hypertension Research

Volume: 31, P: 335-344
Impact of Adenosine Receptor Signaling and Metabolism on Pathophysiology in Patients with Chronic Heart Failure

Masanori Asakura
Hiroshi Asanuma
Masafumi Kitakaze
Research01 Sept 2007
Hypertension Research

Volume: 30, P: 781-787
Abnormal Glucose Tolerance Contributes to the Progression of Chronic Heart Failure in Patients with Dilated Cardiomyopathy

Jiyoong Kim
Satoshi Nakatani
Masafumi Kitakaze
Research01 Oct 2006
Hypertension Research

Volume: 29, P: 775-782
Casein Hydrolysate Containing the Antihypertensive Tripeptides Val-Pro-Pro and Ile-Pro-Pro Improves Vascular Endothelial Function Independent of Blood Pressure–Lowering Effects: Contribution of the Inhibitory Action of Angiotensin-Converting Enzyme

Tatsuhiko Hirota
Kohji Ohki
Masafumi Kitakaze
Research01 Jun 2007
Hypertension Research

Volume: 30, P: 489-496
Plasma Adiponectin Is Associated with Plasma Brain Natriuretic Peptide and Cardiac Function in Healthy Subjects

Takahiro Ohara
Jiyoong Kim
Masafumi Kitakaze
Research01 May 2008
Hypertension Research

Volume: 31, P: 825-831
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy

Masanori Asakura
Masafumi Kitakaze
Shigeki Higashiyama
Research01 Jan 2002
Nature Medicine

Volume: 8, P: 35-40
Inhibition of Cardiac Remodeling by Pravastatin Is Associated with Amelioration of Endoplasmic Reticulum Stress

Hui Zhao
Yulin Liao
Masafumi Kitakaze
Research01 Oct 2008
Hypertension Research

Volume: 31, P: 1977-1987
Plasma indoxyl sulfate levels predict cardiovascular events in patients with mild chronic heart failure

Miki Imazu
Hiroki Fukuda
Masafumi Kitakaze
ResearchOpen Access05 Oct 2020
Scientific Reports

Volume: 10, P: 1-7
Non-linear Equation using Plasma Brain Natriuretic Peptide Levels to Predict Cardiovascular Outcomes in Patients with Heart Failure

Hiroki Fukuda
Hideaki Suwa
Masafumi Kitakaze
ResearchOpen Access15 Nov 2016
Scientific Reports

Volume: 6, P: 1-10
Predicting heart failure onset in the general population using a novel data-mining artificial intelligence method

Yohei Miyashita
Tatsuro Hitsumoto
Masafumi Kitakaze
ResearchOpen Access16 Mar 2023
Scientific Reports

Volume: 13, P: 1-7
Lamr1 functional retroposon causes right ventricular dysplasia in mice

Yoshihiro Asano
Seiji Takashima
Masatsugu Hori
Research18 Jan 2004
Nature Genetics

Volume: 36, P: 123-130
Heart Failure Phenotypes Induced by Knockdown of DAPIT in Zebrafish: A New Insight into Mechanism of Dilated Cardiomyopathy

Yoji Nagata
Masakazu Yamagishi
Kenshi Hayashi
ResearchOpen Access12 Dec 2017
Scientific Reports

Volume: 7, P: 1-9
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

A prespecified analysis of the DELIVER clinical trial shows that the sodium/glucose cotransporter 2 inhibitor dapagliflozin benefits patients categorized as having heart failure with improved ejection fraction, a class of patients at high risk of cardiac events but for which limited treatment data are available.

Orly Vardeny
James C. Fang
Scott D. Solomon
ResearchOpen Access15 Dec 2022
Nature Medicine

Volume: 28, P: 2504-2511
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Orly Vardeny
James C. Fang
Scott D. Solomon
Amendments and CorrectionsOpen Access17 Mar 2023
Nature Medicine

Volume: 29, P: 3269
Augmented AMPK activity inhibits cell migration by phosphorylating the novel substrate Pdlim5

Augmented AMP-activated protein kinase (AMPK) activity inhibits cell migration through an unknown mechanism. Here, Yan et al.show that AMPK phosphorylates the novel substrate PDZ and LIM domain 5 (Pdlim5), and that phosphomimetic Pdlim5 impairs cell migration by disrupting the Rac1-Arp2/3 signalling pathway.

Yi Yan
Osamu Tsukamoto
Seiji Takashima
ResearchOpen Access30 Jan 2015
Nature Communications

Volume: 6, P: 1-14
Heart rate determines the beneficial effects of beta-blockers on cardiovascular outcomes in patients with heart failure and atrial fibrillation

Athanasius Wrin Hudoyo
Hiroki Fukuda
Masafumi Kitakaze
Research18 Jun 2019
Hypertension Research

Volume: 42, P: 1716-1725
Author Correction: Heart Failure Phenotypes Induced by Knockdown of DAPIT in Zebrafish: A New Insight into Mechanism of Dilated Cardiomyopathy

Yoji Nagata
Masakazu Yamagishi
Kenshi Hayashi
Amendments and CorrectionsOpen Access14 May 2018
Scientific Reports

Volume: 8, P: 1
Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial

Shin Ito
Hiroyuki Takahama
Masafumi Kitakaze
ResearchOpen Access02 Aug 2023
Scientific Reports

Volume: 13, P: 1-12
AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation

The microtubule plus end protein CLIP-170 has been shown to be an AMP activated protein kinase (AMPK) substrate. AMPK-mediated phosphorylation of CLIP-170 regulates microtubule polarization and directional cell migration.

Atsushi Nakano
Hisakazu Kato
Seiji Takashima
Research23 May 2010
Nature Cell Biology

Volume: 12, P: 583-590
Plasma B-type natriuretic peptide is a useful tool for assessing coronary heart disease risk in a Japanese general population

Takuya Hasegawa
Masanori Asakura
Masafumi Kitakaze
Research14 Aug 2014
Hypertension Research

Volume: 38, P: 74-79
Usefulness of three-dimensional echocardiography in assessing right ventricular function in patients with primary pulmonary hypertension

Makoto Amaki
Satoshi Nakatani
Masafumi Kitakaze
Research27 Mar 2009
Hypertension Research

Volume: 32, P: 419-422
Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure

Miki Imazu
Hiroyuki Takahama
Masafumi Kitakaze
Research29 Sept 2016
Hypertension Research

Volume: 40, P: 181-188
The role of a common TNNT2 polymorphism in cardiac hypertrophy

Kazuo Komamura
Naoharu Iwai
Kunio Miyatake
Research01 Mar 2004
Journal of Human Genetics

Volume: 49, P: 129-133
The milk-derived peptides Val-Pro-Pro and Ile-Pro-Pro attenuate arterial dysfunction in L-NAME-treated rats

Atsuko Nonaka
Teppei Nakamura
Masafumi Kitakaze
Research03 Apr 2014
Hypertension Research

Volume: 37, P: 703-707
Plasma adiponectin levels predict cardiovascular events in the observational Arita Cohort Study in Japan: the importance of the plasma adiponectin levels

Chun-Yen Chen
Masanori Asakura
Masafumi Kitakaze
Research05 Apr 2012
Hypertension Research

Volume: 35, P: 843-848
ASB2 is a novel E3 ligase of SMAD9 required for cardiogenesis

Kyung-Duk Min
Masanori Asakura
Masafumi Kitakaze
ResearchOpen Access29 Nov 2021
Scientific Reports

Volume: 11, P: 1-15
The impact of creating mathematical formula to predict cardiovascular events in patients with heart failure

Mari Sakamoto
Hiroki Fukuda
Masafumi Kitakaze
ResearchOpen Access05 Mar 2018
Scientific Reports

Volume: 8, P: 1-12
Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial

Yuichi Saito
Atsushi Tanaka
Kosuke Nishio
Research14 Nov 2023
Hypertension Research

Volume: 47, P: 168-176
Reply to ‘Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure’

Miki Imazu
Hiroyuki Takahama
Masafumi Kitakaze
Correspondence27 Apr 2017
Hypertension Research

Volume: 40, P: 900-901
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial

Kazuki Shiina
Hirofumi Tomiyama
Akiomi Yoshihisa
Research15 Nov 2022
Hypertension Research

Volume: 46, P: 495-506
α1-Adrenergic receptor mediates adipose-derived stem cell sheet-induced protection against chronic heart failure after myocardial infarction in rats

Hiromu Horie
Ichiro Hisatome
Motonobu Nishimura
Research01 Dec 2021
Hypertension Research

Volume: 45, P: 283-291
Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models

The authors generated a functional monoclonal antibody that recognizes and promotes the internalization of TRPV2 to reduce TRPV2-driven Ca²⁺ influx. Using cardiomyopathic/muscular dystrophic animal models, they confirmed the beneficial effects of this antibody, which includes improvements in both Ca²⁺ handling in cardiomyocytes and in skeletal muscle properties.

Yuko Iwata
Shigeo Wakabayashi
Masafumi Kitakaze
Research02 Jan 2020
Laboratory Investigation

Volume: 100, P: 324-337
Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition

Jing Ma
Tao Luo
Masafumi Kitakaze
ResearchOpen Access26 Sept 2016
Scientific Reports

Volume: 6, P: 1-12
Btg2 is a Negative Regulator of Cardiomyocyte Hypertrophy through a Decrease in Cytosolic RNA

Yuki Masumura
Shuichiro Higo
Yasushi Sakata
ResearchOpen Access27 Jun 2016
Scientific Reports

Volume: 6, P: 1-13
Derivation of a mathematical expression for predicting the time to cardiac events in patients with heart failure: a retrospective clinical study

Akemi Yoshida
Masanori Asakura
Masafumi Kitakaze
Research20 Dec 2012
Hypertension Research

Volume: 36, P: 450-456
Does the pathophysiology of heart failure prime the incidence of cancer?

Mari Sakamoto
Takuya Hasegawa
Masafumi Kitakaze
Research06 Apr 2017
Hypertension Research

Volume: 40, P: 831-836
Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO

Hiroshi Asanuma
Shoji Sanada
Masafumi Kitakaze
Research03 Apr 2014
Hypertension Research

Volume: 37, P: 716-723
TRPV2 channel as a possible drug target for the treatment of heart failure

Transient receptor potential vanilloid 2 (TRPV2) plays a significant role in the onset and progression of heart failure. In this review, the authors summarize the recent findings on TRPV2 in cardiomyocytes and immune cells involved in the development of heart failure and discuss the current progress of drug development that is aimed at treating heart failure through targeting TRPV2.

Yuko Iwata
Shin Ito
Masafumi Kitakaze
Reviews19 Dec 2019
Laboratory Investigation

Volume: 100, P: 207-217

Search

Filter By:

Search

Quick links